Trial investigators evaluated the prognostic and predictive ability of PAM50 molecular prostate cancer subtypes to guide salvage treatment.
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results